Press Release FeedGet the RSS feed
Menu

PR Newswire

Leidos Holdings, Inc. Increases Quarterly Cash Dividend by 4.7%

Leidos

The board of directors of Leidos Holdings, Inc. (NYSE: LDOS ) declared a quarterly cash dividend of $0.45 per outstanding share of the company's common stock, a $0.02 increase compared to the prior quarterly dividend of $0.43 per share. The cash dividend is payable on December 31, 2026, to stockholders of record as of the close of business on December 15, 2026. About Leidos Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with approximately 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.Leidos.com . Media Contact: Brandon Ver Velde (571) 526-6257 [email protected] Investor Relations: Stuart Davis (571) 526-6124 [email protected] SOURCE Leidos Holdings, Inc.

  1. SustainabilityRooted in Community: Leidos Innovations U.K. Limited and Carma Support Veterans and a Greener FutureCompanies: LeidosNORTHAMPTON, MA / October 30, 2026 / Environmental action can create benefits that reach far beyond the environment. Through its partnership with U.K. climate action provider Carma, Leidos Innovations U.K. Limited is bringing together tree planting, community engagement and support for military veterans.
  2. SustainabilityLeidos Innovations U.K. Limited Demonstrates Environmental Progress Through Technology and Operational EfficiencyCompanies: LeidosNORTHAMPTON, MA / October 28, 2026 / At Leidos Innovations U.K. Limited, environmental sustainability is increasingly connected to innovation, operational efficiency and smarter resource management. The company's 2025 U.K. Sustainability Report highlights a 32% reduction in reported carbon emissions sinc
  3. FinanceLeidos Holdings, Inc.Leidos bringing AI advances to Pentagon logistics systemCompanies: LeidosLeidos (NYSE: LDOS) will deploy artificial intelligence automation to streamline and accelerate the Pentagon asset management system that more than 50 agencies use to manage over 80 million items of government property valued at more than $140...
  4. AIWhy Legacy Pathology Archives Matter for Rare-Disease ResearchCompanies: LeidosWhy Legacy Pathology Archives Matter for Rare-Disease Research Mon, 10/19/2026 - 08:15 Body Why it matters Rare-disease research needs larger, richer historical datasets Digitized archives make decades of evidence searchable Historical tissue can reveal patterns previously missed Pathology archives often contain decades of clinically valuable information that is difficult to access in its original format. Glass slides may reveal evidence of disease patterns and support diagnostic decisions and tissue characteristics that were essential at the time of creation, but as scientific research data they are difficult to search, share and study at scale. As digital pathology matures, those archives are increasingly being viewed differently: not simply as storage, but as valuable research assets. Archives hold more than history This shift is significant because some of the most important questions in medicine cannot be answered with a small sample set. Rare diseases, unusual presentations and long-term retrospective analysis often require access to large collections of historical material. When slides are digitized, they become easier to review, compare, and organize for broader scientific use. Most importantly, not all slides need to be collocated for research as the data can be shared digitally. What was once a physical archive can begin to function as a structured digital dataset. This is where ScanVan™ excels. ScanVan is Leidos’ high-throughput whole-slide digitization platform, designed to bring scanning capability directly to the archive and help convert large volumes of glass slides into digital assets without requiring the collection to be moved off-site. In that sense, ScanVan is not the story itself; it is the operational example of how large-scale archive digitization can happen in practice. The opportunity is impactful for hospital systems and pharmaceutical organizations that are interested in retrospective research, biomarker discovery and future AI-enabled analysis. Digital pathology makes it easier to examine archived tissue in a consistent format, identify patterns across cases and connect specimen-level information to the larger research environment. The larger and more organized the archive, the more useful it becomes for research teams trying to understand rare conditions, compare historical samples or generate hypotheses for future studies. Unlocking value that’s already there A platform like ScanVan supports high-volume digitization in a way that is practical for large, complex archives. The work still has to be done carefully—with strong attention to image quality, chain of custody and operational control—but once the archive is digitized, it becomes a resource that can be used in new ways. In that sense, legacy pathology archives represent an untapped source of scientific value. They are already rich with information. Digitization simply makes that information easier to see, study and apply. For health systems, the question is no longer whether the archive has value. The question is how to unlock it. ScanVan by the numbers Developed in collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence, ScanVan is designed for collections ranging from thousands to millions of slides. Based on 12-hour scanning days, Monday through Friday, the platform can digitize: More than 16,000 slides per week More than 67,000 slides per month More than 800,000 slides per year These figures demonstrate the operational scale required to turn a legacy archive into a usable research resource. Three things to remember Digitized slides can be shared and studied without physically collocating pathology collections Archive digitization requires strong image quality, chain-of-custody and operational controls ScanVan enables high-volume slide digitization while keeping pathology archives on-site LEARN MORE ABOUT SCANVAN Canonical URL https://www.leidos.com/insights/why-legacy-pathology-archives-matter-rare-disea… Featured Image Type of Content Article
  5. FinanceBlackstone Credit & Insurance Leads $1 Billion Financing to Support Combination of Analogic Corporation and Leidos' Security Enterprise Solutions BusinessesCompanies: LeidosBlackstone Inc.Blackstone Credit & Insurance (“BXCI”) announced that it is leading a $1 billion financing in support of the combination of Analogic Corporation (“Analogic”) with the Security Enterprise Solutions, Ports & Borders and Industrial Automation businesses of Leidos Holdings, Inc. (NYSE: LDOS) (“Leidos”). The combination creates a stronger global security imaging and detection company with broader capabilities, deeper customer relationships and greater scale to support customers across airports,... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=362762
  6. FinanceLeidosLeidos Security Enterprise Solutions and Analogic close deal to strengthen global security screening capabilitiesCompanies: LeidosLeidos (NYSE: LDOS) and investment firm Altaris have completed their previously announced transaction to form a scaled U.S.-based joint venture (JV) for advancing security screening at airports, borders and critical infrastructure worldwide....